1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108
2. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642
3. Mottet NBJ, Briers E, Bolla M, Cornford P, De Santis M, Henry A, Joniau A, Lam T, Mason MD, Matveev V, van der Kwast TH, van der Poel H, Rouvière O, Wiegel T; members of the EAU–ESTRO–SIOG prostate cancer guidelines Panel., EAU–ESTRO–SIOG guidelines on prostate cancer. Edn. Presented at the EAU Annual Congress MI—PEGO.
https://uroweb.org/guideline/prostate-cancer/
. Accessed 26 Mar 2017
4. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395
5. Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6(Suppl 10):S13–S18